-
Rocket-Like Nanomedicine Reprograms PDAC Stroma
2026-09-04
Fu and colleagues developed an acid-responsive, sequential-release nanomedicine that remodels pancreatic ductal adenocarcinoma stroma before delivering gemcitabine. In a PDAC mouse model, the Si-G@Ca-H/uPA platform produced marked tumor regression without reported overt side effects, supporting stromal reprogramming as an alternative to nonspecific stromal depletion.
-
Predicting siRNA Encapsulation with Netarsudil
2026-09-04
Slaughter et al. introduce a quantitative framework for predicting when ionizable drugs can complex siRNA and function as drug-containing nanoparticle components. Netarsudil (AR-13324) served as an experimental validation agent, enabling codelivery of CTGF-targeting siRNA and reducing CTGF expression and actin-network density in fibrotic human trabecular meshwork cells.
-
Merbromin Assay Design: From Signal to Evidence
2026-09-03
Merbromin is a versatile biochemical research fluorescent dye and protein–ligand interaction probe. This guide shows how to translate its fluorescence, absorption, and resonance Rayleigh scattering behavior into better pharmaceutical, enzymatic, and antiviral assay decisions.
-
BRD4 Inhibitors Sensitize Cells to Erastin Ferroptosis
2026-09-03
The reference study shows that pharmacological BRD4 inhibition and BRD4 knockdown broadly enhance erastin-induced ferroptosis across several human cell lines. Its mechanistic contribution is the identification of increased reactive oxygen species and reduced FSP1 expression as convergent features, while also revealing cell-specific changes in other ferroptosis-associated genes.
-
Bafilomycin A1: From V-ATPase to Translation
2026-09-02
A mechanistic and translational framework for using Bafilomycin A1 to connect V-ATPase activity, intracellular pH regulation, lysosomal function, oxidative stress, and autophagy while preserving experimental rigor.
-
Platelet Extravasation in Tumors: CXCR4 and Growth
2026-09-02
The reference study defines platelet transendothelial migration into tumors as a regulated process controlled by CXCL12/CXCR4, FAK, PECAM-1, and vessel-stabilizing pathways. Its central contribution is to separate platelet trafficking from platelet effector activity, showing that distinct granule-release programs independently influence tumor growth and vascular integrity.
-
A Proximity MAP of RAB GTPases: Key Findings
2026-09-01
The preprint A Proximity MAP of RAB GTPases applies APEX2 proximity labeling across 23 human RAB GTPases to build a comparative map of their neighboring proteomes. Its validation of RAB25–DENND6A, RAB14–EARP, and RAB14–SHIP164/UHRF1BP1 relationships illustrates how proximity proteomics can generate testable models of membrane-trafficking regulation.
-
α2-AR Agonism in Osteosarcoma Research
2026-09-01
A translational perspective on how α2-adrenergic receptor activation may shift osteosarcoma recurrence research from direct tumor-cell killing toward immune-context engineering, with practical guidance for using B3465 in receptor, immune, and hydrogel-based studies.
-
CX-5461 Drives DNA Damage in Cervical Cancer
2026-08-31
A June 2026 study identifies a mechanistic link between Pol I transcription inhibition, DNA damage, and mitotic catastrophe in cervical cancer cells. The work also shows that CX-5461 can increase cisplatin sensitivity, supporting further investigation of ribosome-biogenesis stress as a strategy for treatment-resistant disease.
-
C34 TLR4 Inhibitor: An Assay-First Guide
2026-08-31
C34 is a selective TLR4 inhibitor for dissecting receptor-specific inflammatory signaling. This assay-first guide connects macrophage and enterocyte studies with new neuroinflammation evidence while emphasizing controls, interpretation, and translational limits.
-
Acetylspiramycin: Workflows and Resistance Insights
2026-08-30
Acetylspiramycin, or Spiramycin B, is a ribosome-directed macrolide tool for connecting susceptibility phenotypes with resistance biology and host-response experiments. This guide presents practical broth microdilution workflows, stock-handling controls, and a compartment-aware interpretation framework inspired by a published ocular infection case.
-
Naloxone hydrochloride Research Workflows
2026-08-29
Build cleaner opioid receptor, neural stem cell, immune, and behavioral assays with a single, well-characterized antagonist. This guide distinguishes receptor-dependent effects from TET1-linked neural responses and adds practical controls for concentration, solvent, timing, and interpretation.
-
CX-5461 Triggers Mitotic Catastrophe in Cervical Cancer
2026-08-28
A June 2026 study identifies a distinctive mechanism by which the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cells: DNA damage is coupled to abnormal mitotic entry, producing mitotic catastrophe, cell death, or senescence. The work also shows that CX-5461 increases cisplatin sensitivity, providing a rationale for combination strategies in treatment-resistant disease.
-
BET Inhibition in HPV-16-Associated HNSCC
2026-08-28
A bioRxiv preprint examines how BET protein inhibition alters viral and host transcription in HPV-16-associated head and neck squamous cell carcinoma. Its central finding is that BET blockade suppresses E6 and E7 but produces heterogeneous responses in p53, Rb, and viral transcription, supporting a more stratified approach to therapeutic interpretation.
-
Anti-HMGB1 Rabbit Monoclonal Antibody Guide
2026-08-27
This guide explains how to use the Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, for HMGB1 detection in Western blot, immunohistochemistry, and flow cytometry workflows. It is intended for research use with human, mouse, and rat samples, not for diagnosis, therapy, or clinical decision-making; no directly matched paper evidence was available for this specific SKU.